TodayLocalMarylandSilver Spring
Maryland
Good news from Silver Spring, Maryland: 9 verified stories, each one checked and linked to the original report.
Health & TechJemperli, or dostarlimab, received accelerated approval for untreated stage II or III dMMR or MSI-H rectal cancer. In a 154-patient trial, nearly three-fourths needed no chemo, radiation, or surgery after more than two years. That subtype is about 3 percent of rectal cancers.
Verified · U.S. Food and Drug Administration
Health & TechThe FDA expanded Anktiva, given with BCG, to adults with BCG-unresponsive high-grade papillary-only bladder cancer. A related trial, not this exact group, saw a 62 percent complete response.
Verified · U.S. Food and Drug Administration
Health & TechZanvastro (zilganersen) is approved for a rare, often fatal brain disorder. In a controlled trial, treated patients 5 and older with walking trouble were faster at 61 weeks, and treated 2- to 4-year-olds gained motor skills while untreated children declined. It is not a cure.
Verified · Nature Biotechnology
Health & TechOn October 9 the FDA approved Teva's Weltruza, a long-acting injection for adults with schizophrenia. Teva expects a U.S. launch within weeks. It is not a cure.
Verified · CNBC
Health & TechHovilpri (pritelivir) is for immunocompromised adults whose lesions did not respond to acyclovir, valacyclovir, or famciclovir. The trial was open-label, and herpes still has no cure.
Verified · U.S. Food and Drug Administration
Health & TechIn a 712-patient trial, adding atezolizumab to chemotherapy after surgery halved the risk of the cancer returning or of death. Median disease-free survival was not reached, and overall survival was not the result reported.
Verified · U.S. Food and Drug Administration
Health & TechIn a 654-person maintenance trial, median progression-free survival was 24.9 months with tucatinib and 16.3 months with placebo. Overall survival is not known yet.
Verified · U.S. Food and Drug Administration
Health & TechIn a 282-person trial, the cancer took longer to worsen than with a common chemoimmunotherapy. Survival is not proven, and the approval excludes a 17p deletion.
Verified · U.S. Food and Drug Administration
Health & TechIn a study of 62 children, the Autus valve met the FDA's six-month bar. Only two have been expanded so far, and longer follow-up is still underway.
Verified · U.S. Food and Drug Administration